Connecting via Winsock to STN

Welcome to STN International! Enter x:x

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	4	OCT 03	MATHDI removed from STN
NEWS	5	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS	8	OCT 27	Free KWIC format extended in full-text databases
NEWS	9	OCT 27	DIOGENES content streamlined
NEWS	10	OCT 27	EPFULL enhanced with additional content
NEWS	11	NOV 14	CA/CAplus - Expanded coverage of German academic research
NEWS	12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS	13	DEC 05	CASREACT(R) - Over 10 million reactions available

NEWS EXPRESS	DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:27:57 ON 05 DEC 2005

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?

```
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:28:12 ON 05 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     4 DEC 2005  HIGHEST RN 869277-23-6
DICTIONARY FILE UPDATES:    4 DEC 2005  HIGHEST RN 869277-23-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10526938.str
```



chain nodes :
9 10 11 12 13 14 16 17 18 19 20 21 22 23 24 25 26 27 32 35
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
1-16 6-9 9-10 10-11 11-12 12-13 13-14 13-17 14-32 14-35 18-22 18-21
18-35 19-23 19-20 19-32 20-25 21-24 24-26 25-27
ring bonds :
1-2 1-3 2-4 3-5 4-5 4-6 5-8 6-7 7-8
exact/norm bonds :
1-2 1-3 1-16 2-4 3-5 4-5 4-6 5-8 6-7 7-8 13-14 13-17 18-22 18-21
19-23 19-20
exact bonds :
6-9 9-10 10-11 11-12 12-13 14-32 14-35 18-35 19-32 20-25 21-24 24-26
25-27
isolated ring systems :
containing 1 :

G1:O,NH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
32:CLASS 35:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,NH

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:28:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      151 TO ITERATE

100.0% PROCESSED      151 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2283 TO     3757
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 12:28:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     3292 TO ITERATE

100.0% PROCESSED     3292 ITERATIONS                                 13 ANSWERS
SEARCH TIME: 00.00.01

L3            13 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     161.33     161.54

FILE 'CAPLUS' ENTERED AT 12:28:56 ON 05 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 5 Dec 2005 VOL 143 ISS 24
FILE LAST UPDATED: 4 Dec 2005 (20051204/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 1 L3

=> d l1 ibib abs hitstr tot
L1 HAS NO ANSWERS
'IBIB ABS HITSTR ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
Structure Formats
SIA ----- Structure Image, Attributes, and map table if it contains
data. (Default)
SIM ----- Structure IMage.
SAT ----- Structure ATtributes and map table if it contains data.
SCT ----- Structure Connection Table and map table if it contains
data.
SDA ----- All Structure DAta (image, attributes, connection table and
map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIM), NOS:end

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:220338 CAPLUS
DOCUMENT NUMBER: 140:271147
TITLE: Multipurpose biotin-containing linker compounds and ligands containing oligosaccharides and biotin and process for producing the same
INVENTOR(S): Suda, Yasuo; Arano, Akio; Hayashi, Hideki; Kusumoto, Shoichi; Sobel, Michael
PATENT ASSIGNEE(S): Japan Science and Technology Corporation, Japan; Japan as Represented by the President of Kagoshima University
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022565	A1	20040318	WO 2003-JP9973	20030806

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2004155762	A2	20040603	JP 2003-190637	20030702
CA 2500197	AA	20040318	CA 2003-2500197	20030806
EP 1548016	A1	20050629	EP 2003-794076	20030806

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:
JP 2002-263414 A 20020909
JP 2003-190637 A 20030702
WO 2003-JP9973 W 20030806

OTHER SOURCE(S): MARPAT 140:271147

GI



I



II

AB Disclosed is a multipurpose linker compound having a structure represented by the following general formula (I) (wherein Y has a structure represented by O or NH; X has a multibranched site structure involving 4 hydrocarbon derivative chains each having an aromatic amino group at the end and optionally having a carbon-nitrogen bond in the main chain). This multipurpose linker compound makes it possible to two-dimensionally align saccharide mols. at a high reproducibility on the surface of a support for protein anal. Also disclosed is a ligand in which saccharide mols. have been introduced into the above-described multipurpose linker compound Also claimed are a sensor chip for detecting the interaction of oligosaccharides by surface plasmon resonance or affinity chromatog. column in which the above biotin-linked oligosaccharide ligands are introduced and fixed on the surface of a support having streptavidin or avidin immobilized. Thus, reductive amination of a biotin-containing linker (II; R = H) with glucose, maltose, or lactose using sodium cyanoborohydride in aqueous AcOH/MeOH gave ligands II (R = Q; R1 = OH, α-D-glucopyranosyloxy, or β-D-galactopyranosyloxy). The latter two ligands, i.e. II (R = Q; R1 = OH) and II (R = Q, R1 = α-D-glucopyranosyloxy) were introduced on a sensor chip comprising a avidin (NeutrAvidin)-linked gold thin film vapor-deposited on a glass substrate and their interaction with Con A was studied using surface plasmon resonance.

IT **672295-58-8DP**, bound on Hitrap NHS-activated Hp
RL: ARU (Analytical role, unclassified); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
(affinity column; preparation of multipurpose biotin-containing linkers and ligands containing oligosaccharides and biotin for affinity chromatog. column and sensor chips in protein anal. by surface plasmon resonance)

RN 672295-58-8 CAPLUS

CN D-Glucitol, 1,1',1'',1'''-[[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]imino]bis[(1-oxo-3,1-propanediyl)imino-2,1-ethanediylnitrilobis[(1-oxo-3,1-propanediyl)imino-3,1-phenyleneimino]]]tetrakis[1-deoxy-4-O-α-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







chain nodes :
9 10 11 12 13 14 16 17
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
1-16 6-9 9-10 10-11 11-12 12-13 13-14 13-17
ring bonds :
1-2 1-3 2-4 3-5 4-5 4-6 5-8 6-7 7-8
exact/norm bonds :
1-2 1-3 1-16 2-4 3-5 4-5 4-6 5-8 6-7 7-8 13-14 13-17
exact bonds :
6-9 9-10 10-11 11-12 12-13
isolated ring systems :
containing 1 :

G1:O,NH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 O,NH

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Dec 2005 VOL 143 ISS 24
FILE LAST UPDATED: 4 Dec 2005 (20051204/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l10
L11       3493 L10

=> s l11 and branched
          71123 BRANCHED
              1 BRANCHEDS
          71124 BRANCHED
                  (BRANCHED OR BRANCHEDS)
L12          29 L11 AND BRANCHED

=> s l11 and branch?
         177082 BRANCH?
L13          39 L11 AND BRANCH?

=> s l13 and (sugar or monosaccharide or oligosaccharide or polysaccharide)
         244646 SUGAR
         127419 SUGARS
         314549 SUGAR
                  (SUGAR OR SUGARS)
          10755 MONOSACCHARIDE
          17112 MONOSACCHARIDES
          22171 MONOSACCHARIDE
                  (MONOSACCHARIDE OR MONOSACCHARIDES)
          28090 OLIGOSACCHARIDE
          42337 OLIGOSACCHARIDES
          50713 OLIGOSACCHARIDE
                  (OLIGOSACCHARIDE OR OLIGOSACCHARIDES)
          56209 POLYSACCHARIDE
          69948 POLYSACCHARIDES
          88511 POLYSACCHARIDE
                  (POLYSACCHARIDE OR POLYSACCHARIDES)
L14           5 L13 AND (SUGAR OR MONOSACCHARIDE OR OLIGOSACCHARIDE OR POLYSACCH
                ARIDE)

=> s l11 and ?branch?
         186071 ?BRANCH?
L15          40 L11 AND ?BRANCH?

=> s l15 and (sugar or monosaccharide or oligosaccharide or polysaccharide)
         244646 SUGAR
         127419 SUGARS
         314549 SUGAR
                  (SUGAR OR SUGARS)
          10755 MONOSACCHARIDE
          17112 MONOSACCHARIDES
          22171 MONOSACCHARIDE
                  (MONOSACCHARIDE OR MONOSACCHARIDES)
          28090 OLIGOSACCHARIDE
          42337 OLIGOSACCHARIDES
          50713 OLIGOSACCHARIDE
                  (OLIGOSACCHARIDE OR OLIGOSACCHARIDES)
```

```
          56209 POLYSACCHARIDE
          69948 POLYSACCHARIDES
          88511 POLYSACCHARIDE
                (POLYSACCHARIDE OR POLYSACCHARIDES)
L16           6 L15 AND (SUGAR OR MONOSACCHARIDE OR OLIGOSACCHARIDE OR POLYSACCH
                ARIDE)

=> s l16 not l4
L17           5 L16 NOT L4

=> d l17 ibib abs hitstr tot

L17  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2005:146298  CAPLUS
TITLE:                    Oligosaccharide mimics containing galactose
                          and fucose specifically label tumour cell surfaces and
                          inhibit cell adhesion to fibronectin
AUTHOR(S):                Kim, Evelyn Y.-L.; Gronewold, Claas; Chatterjee,
                          Amitava; Von der Lieth, Claus-Wilhelm; Kliem,
                          Christian; Schmauser, Birgit; Wiessler, Manfred; Frei,
                          Eva
CORPORATE SOURCE:         Molecular Toxicology, Deutsches
                          Krebsforschungszentrum, Heidelberg, 69120, Germany
SOURCE:                   ChemBioChem (2005), 6(2), 422-431
                          CODEN: CBCHFX; ISSN: 1439-4227
PUBLISHER:                Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   With the aim of establishing a versatile and easy synthesis of
     branched saccharides for biol. applications, we used mol.-dynamics
     simulations to model Lewisy to two classes of dior triantennary saccharide
     mimetics. One set of mimetics was based on 1,3,5-
     tris(hydroxymethyl)cyclohexane (TMC) as the core, the other on furan, and
     both were derivatized with galactose and/or fucose. The TMC-based
     saccharides were biotinylated, while the furan disaccharides were treated
     with maleimide-activated biotin in a Diels-Alder fashion to yield
     oxazatricyclodecanes (OTDs). These were then assayed as cell-surface
     labels in human colon (SW480 and CaCo-2), liver (PLC), Glia (U333 CG 343)
     and ovary (SKOV-3) tumor cell lines. Discrete staining patterns were
     observed in all cells, usually at one or two poles of the cells, particularly
     with the asym. 3-β-L-fucopyranosyloxymethyl-4-β-D-
     galactopyranosyloxymethyl-OTD. Normal SV40-transformed fibroblasts (SV80)
     showed no staining. Adhesion of the highly metastatic mouse melanoma line
     B16F10 to fibronectin was inhibited by 80% by the TMC-digalactoside and by
     30% by 3,4-bis-(β-D-galactopyranosyloxymethyl)furan. None of the
     saccharide mimetics inhibited the adhesion of the less metastatic B16F1
     line. Migration of B16F10 cells through Matrigel was greatly inhibited by
     the TMC-digalactoside and weakly inhibited by the TMC-trigalactoside. The
     saccharide mimetics that had shown the best structural agreements with the
     terminal saccharides of Lewisy in the mol. dynamics simulation were also
     the most biol. potent compds.; this underlines the predictive nature of
     mol. dynamics simulations. The use of the non-saccharide cores enabled us
     to adapt spacer lengths and terminal saccharides to optimize the
     structures to bind more avidly to cell-surface lectins.
IT   INDEXING IN PROGRESS
IT   869202-33-5 869202-34-6 869202-35-7
     869202-36-8
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (preparation and mol. dynamics simulation of oligosaccharide
        mimetics containing galactose and fucose and characterization of tumor cell
        surface labeling and inhibition of cell adhesion to fibronectin)
RN   869202-33-5  CAPLUS
```

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 869202-34-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 869202-35-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 869202-36-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A





IT **72040-63-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and mol. dynamics simulation of **oligosaccharide** mimetics containing galactose and fucose and characterization of tumor cell surface labeling and inhibition of cell adhesion to fibronectin)
RN 72040-63-2 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:566663 CAPLUS
DOCUMENT NUMBER: 141:106736
TITLE: Three-**branched sugar**-chain asparagine derivatives, the **sugar**-chain asparagines, the **sugar** chains, and processes for producing these
INVENTOR(S): Kajihara, Yasuhiro; Kakehi, Kazuaki; Fukae, Kazuhiro
PATENT ASSIGNEE(S): Otsuka Chemical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058824	A1	20040715	WO 2003-JP16912	20031226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511655	AA	20040715	CA 2003-2511655	20031226
EP 1577324	A1	20050921	EP 2003-782926	20031226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: JP 2002-378203 A 20021226
WO 2003-JP16912 W 20031226

OTHER SOURCE(S): MARPAT 141:106736

AB The invention relates to a three-**branched sugar**-chain asparagine derivative in which the N of an amino group of asparagine has been modified with a lipid-soluble protective group, biotin group, or FITC group; a three-**branched sugar**-chain asparagine derivative which is the three-**branched sugar**-chain asparagine derivative having at least one fucose bonded to an N-acetylglucosamine on the non-reducing end group side of the **sugar**-chain asparagine; these **sugar**-chain asparagines; and the **sugar** chains.

IT **719288-52-5P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(manufacture of three-**branched sugar**-chain asparagine derivs.)

RN 719288-52-5 CAPLUS

CN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→6)-O-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)]-α-D-mannopyranosyl-(1→3)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







PAGE 2-A



PAGE 2-B



L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:339444 CAPLUS
DOCUMENT NUMBER: 130:343042
TITLE: Biocompatible polymeric coatings for cell culture substrate and medical devices
INVENTOR(S): Domb, Abraham Jacob
PATENT ASSIGNEE(S): Alomone Labs Ltd., Israel
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 914835	A2	19990512	EP 1998-309089	19981105
EP 914835	A3	20010321		
EP 914835	B1	20050824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IL 122153	A1	20050320	IL 1997-122153	19971110
AT 302623	E	20050915	AT 1998-309089	19981106
US 6127448	A	20001003	US 1998-189101	19981109

PRIORITY APPLN. INFO.: IL 1997-122153 A 19971110

AB The invention provides a biocompatible polymeric coating material selected from the group consisting of linear, dendrimeric and **branched** polymers which contain primary, secondary, tertiary or quaternary amine groups with hydrophobic side chains and which polymers are insol., or only slightly soluble, in aqueous solution at pH 3-11 and soluble in at least one organic solvent selected from the group consisting of alcs., acetone, Me Et ketone, THF, dioxane, chloroform, dichloromethane, hexanes, mixts. thereof and mixts. of any of the above with water. The invention also provides the use of such a polymeric material in a biocompatible coating composition for substrates such as a cell growth culture substrate or a medical device. The cell adhesion properties of polystyrene plates coated with various polyamine derivs. (e.g. stearyl and pentyl derivs. of polyethylenimine and polyvinylamine) were tested using PC12 neuronal cells.

IT **224312-24-7**
RL: DEV (Device component use); POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible polymeric coatings for cell growth culture substrate and medical devices)

RN 224312-24-7 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, 2-(2-methyl-1-oxo-2-propenyl)hydrazide, (3aS,4S,6aR)-, polymer with 2-(dimethylamino)ethyl 2-methyl-2-propenoate and dodecyl 2-methyl-2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 224312-23-6
CMF C14 H22 N4 O3 S

Absolute stereochemistry.



CM 2

CRN 2867-47-2
CMF C8 H15 N O2



CM 3

CRN 142-90-5
CMF C16 H30 O2



L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:349670 CAPLUS
DOCUMENT NUMBER: 125:34044
TITLE: Preparation of tetrasaccharide conjugates as inhibitors of cell adhesion.
INVENTOR(S): Kretzschmar, Gerhard; Schmidt, Wolfgang; Sprengard, Ulrich; Bartnick, Eckart; Seiffge, Dirk; Kunz, Horst
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Ger. Offen., 31 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4436164	A1	19960411	DE 1994-4436164	19941010
US 5858994	A	19990112	US 1995-509079	19950731
EP 714903	A1	19960605	EP 1995-115588	19951004
EP 714903	B1	20020515		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 217630	E	20020615	AT 1995-115588	19951004
CA 2160100	AA	19960411	CA 1995-2160100	19951006
JP 08325286	A2	19961210	JP 1995-261763	19951009
PRIORITY APPLN. INFO.:			DE 1994-4436164 A	19941010

OTHER SOURCE(S): MARPAT 125:34044
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB ZY(CH2)n(NHCO)pR2 [Z = **branched** tetrasaccharide residue; Y = O, NHCO; R2 = amino acid or oligopeptide residue, (cyclo)aliphatic residue, combination of aliphatic and heterocyclic residues, triphenylmethane dye; when Y = O and p = 1, then n = 2-10; when Y = NHCO and p = 0, n = 0-10; when Y = NHCO and p = 1, then n = 1-10], were prepared for treatment and diagnosis of diseases dependent on cell-cell adhesion, and as synthetic vaccines. Thus, title compound (I; R1 = H-Arg-Gly-Asp-Ala-), prepared via lactone (II), inhibited HL60 cell adhesion to recombinant P-selectin with IC50 = 0.01 mM.

IT **176244-96-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrasaccharide conjugates as inhibitors of cell adhesion)

RN 176244-96-5 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-O-[6-deoxy-α-L-galactopyranosyl-(1→3)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]hexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:837578 CAPLUS
DOCUMENT NUMBER: 123:334348
TITLE: Methods for the solid phase synthesis of glycoconjugates
INVENTOR(S): Vetter, Dirk; Tumelty, David; Antonenko, Valery
PATENT ASSIGNEE(S): Affymax Technologies N.V., Neth.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9518971	A1	19950713	WO 1995-US484		19950110
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US					
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9516029	A1	19950801	AU 1995-16029		19950110
PRIORITY APPLN. INFO.:			US 1994-179741	A	19940111
			US 1994-201607	A	19940225
			WO 1995-US484	W	19950110

OTHER SOURCE(S): CASREACT 123:334348
AB An efficient and versatile method of forming N-linked glycoconjugates is described wherein a glycosyl acceptor, typically comprising an activated carboxyl group, is reacted with a glycosylating agent, typically a glycosyl amine, in the presence of a coupling catalyst and optionally an exogenous base. Depending on the choice of reactive site, this method can be used to form N-linked glycoconjugates, in either a soluble or substrate-bound, linear or **branched** format.
IT **72040-63-2**, N-Hydroxysuccinimidyl biotinamidocaproate
RL: RCT (Reactant); RACT (Reactant or reagent)
(methods for solid-phase synthesis of glycoconjugates)
RN 72040-63-2 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **168636-40-6P 168636-41-7P 168636-42-8P**
168636-43-9P 168636-44-0P 168636-45-1P
168636-46-2P 168636-47-3P 168636-48-4P
168636-49-5P 168636-50-8P 168636-51-9P
168636-52-0P 168636-53-1P 168636-54-2P
168636-55-3P 168636-56-4P 168636-57-5P
168636-58-6P 168636-59-7P 168636-60-0P
168636-61-1P 168636-62-2P 168636-63-3P
168636-64-4P 168636-65-5P 168636-66-6P
168636-67-7P 168636-68-8P 168752-70-3P
168752-71-4P 168752-72-5P 168752-73-6P
168752-74-7P 168752-75-8P 168752-76-9P
168752-77-0P 168752-78-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(methods for solid-phase synthesis of glycoconjugates)

RN 168636-40-6 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-(D-glucopyranosylamino)-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-41-7 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(6-deoxy-L-galactopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-42-8 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-43-9 CAPLUS
CN α-Neuraminic acid, N-acetyl-2-deoxy-2-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168636-44-0 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(N-acetylmuramosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-45-1 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-3-O-sulfo-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-46-2 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-6-O-sulfo-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-47-3 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-deoxy-3-O-sulfo-2-(sulfoamino)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-48-4 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-deoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-49-5 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-2-oxo-N-[6-oxo-6-[(6-O-phosphono-D-mannopyranosyl)amino]hexyl]-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-50-8 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-2-oxo-N-[6-oxo-6-[(6-O-sulfo-D-galactopyranosyl)amino]hexyl]-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-51-9 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(4-O-α-D-glucopyranosyl-D-glucopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-52-0 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(O-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1→4)-D-glucopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 168636-53-1 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 168636-54-2 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 168636-55-3 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 168636-56-4 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[6-[[4-O-(2-O-methyl-β-D-galactopyranosyl)-D-glucopyranosyl]amino]-6-oxohexyl]-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-57-5 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-4-O-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-2-deoxy-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-58-6 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-4-O-β-D-galactopyranosyl-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-59-7 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-6-O-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-2-deoxy-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-60-0 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-3-O-β-D-galactopyranosyl-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-61-1 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-6-O-β-D-galactopyranosyl-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-62-2 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[6-O-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-D-galactopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-63-3 CAPLUS
CN D-Galactopyranuronic acid, 1-deoxy-4-O-α-D-galactopyranuronosyl-1-

[[6-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]-1-oxohexyl]amino]-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-64-4 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(6-O-β-D-galactopyranosyl-D-galactopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168636-65-5 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1→4)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



PAGE 1-B



RN 168636-66-6 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(O-6-deoxy-α-L-galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1→4)-O-6-deoxy-α-L-galactopyranosyl-(1→3)-D-glucopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 168636-67-7 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[O-β-D-

galactopyranosyl-(1→3)-O-6-deoxy-α-L-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1→4)-D-glucopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 168636-68-8 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[6-[(3-O-α-D-mannopyranosyl-D-mannopyranosyl)amino]-6-oxohexyl]-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168752-70-3 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-(D-galactopyranosylamino)-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168752-71-4 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-D-galactopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168752-72-5 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-D-mannopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168752-73-6 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-D-allopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168752-74-7 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-2-oxo-N-[6-oxo-6-[(6-O-phosphono-D-galactopyranosyl)amino]hexyl]-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168752-75-8 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(4-O-β-D-glucopyranosyl-D-glucopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168752-76-9 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(4-O-α-D-galactopyranosyl-D-galactopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168752-77-0 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[[2-(acetylamino)-2-deoxy-3-O-β-D-galactopyranosyl-D-galactopyranosyl]amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



RN 168752-78-1 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[6-[(4-O-β-D-galactopyranosyl-D-glucopyranosyl)amino]-6-oxohexyl]hexahydro-2-oxo-, [3aS-(3aα,4β,6aα)]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	50.89	384.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.65	-4.38

STN INTERNATIONAL LOGOFF AT 12:44:00 ON 05 DEC 2005